Get the Stockscreener App
5.32
3.80%
-0.21
Precigen Inc stock is traded at $5.32, with a volume of 3.45M.
It is down -3.80% in the last 24 hours and up +36.76% over the past month.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
See More
Previous Close:
$5.53
Open:
$5.5
24h Volume:
3.45M
Relative Volume:
0.79
Market Cap:
$1.90B
Revenue:
$9.68M
Net Income/Loss:
$-250.64M
P/E Ratio:
-3.8005
EPS:
-1.3998
Net Cash Flow:
$-89.83M
1W Performance:
-5.67%
1M Performance:
+36.76%
6M Performance:
+15.90%
1Y Performance:
+178.53%
1-Day Range:
$5.17
$5.50
1-Week Range:
$5.17
$5.795
52-Week Range:
$1.47
$6.04
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
5.32 | 1.90B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Precigen (PGEN) In Focus As Russell Removal Tests Its Undervalued Narrative - simplywall.st
Precigen Inc (NASDAQ:PGEN) Flashes Perfect Technical Rating and Explosive Sales Growth in Minervini Screen - ChartMill
Precigen Inc. (PGEN) Edges Higher as Biotech Sector Attention IntensifiesMotive Wave - dars.gov.et
Precigen reports $3.4M in PAPZIMEOS sales for Q4 2025 - Investing.com
PGENPrecigen Inc Latest SEC Filings - Finviz
Precigen Insider Sold Shares Worth $2,042,864, According to a Recent SEC Filing - marketscreener.com
Precigen Insider Sold Shares Worth $1,113,143, According to a Recent SEC Filing - Moomoo
Precigen CFO Harry Thomasian Jr. sells $1.1m in company stock - Investing.com UK
Insider Sell Alert: Harry Thomasian Sells 200,000 Shares of Prec - GuruFocus
Precigen CEO Helen Sabzevari sells $2.04m in PGEN stock - Investing.com
Precigen COO Rutul Shah sells $251,105 in company stock - Investing.com
Precigen (PGEN) COO sells 42,924 shares after option exercise - Stock Titan
Precigen COO Rutul Shah sells $251,105 in company stock By Investing.com - Investing.com South Africa
Form 4 Precigen Inc For: 1 July By Investing.com - Investing.com Nigeria
Precigen CEO Helen Sabzevari sells $2.04m in PGEN stock By Investing.com - Investing.com India
[Form 4] PRECIGEN, INC. Insider Trading Activity - Stock Titan
Precigen (PGEN) CFO executes 200,000-share open-market sale under 10b5-1 plan - Stock Titan
Form 144 PRECIGEN For: 1 July By Investing.com - Investing.com Nigeria
PGEN (NASDAQ) affiliate files Rule 144 notice to sell 28,571 shares - Stock Titan
Does Precigen’s (PGEN) Russell Value Index Exit Signal a Shifting Investor Base or Story? - simplywall.st
[144] PRECIGEN, INC. SEC Filing - Stock Titan
Form 144 PRECIGEN For: 29 June By Investing.com - Investing.com South Africa
Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell 2500 Value Benchmark - marketscreener.com
Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell 3000E Value Benchmark - marketscreener.com
Precigen: Entering The Oncology "Sweet Spot" (NASDAQ:PGEN) - Seeking Alpha
PGEN Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Precigen, Inc. – NASDAQ:PGEN - TradingView
Precigen Inc Actuals & Estimates (BX:I5X) - TradingView
Price to earnings forward of Precigen, Inc. – NASDAQ:PGEN - TradingView
Precigen Shareholders Expand Incentive Plan, Reaffirm Governance - The Globe and Mail
Precigen (PGEN) investors back 7M-share incentive pool and all board picks - Stock Titan
Clearfield And 2 Insider Picks For Strong Growth - simplywall.st
Precigen (PGEN) Is Up 12.1% After Orphan Exclusivity Win for PAPZIMEOS TherapyWhat's Changed - Sahm
Precigen stock hits 52-week high at 5.47 USD By Investing.com - Investing.com Australia
Precigen stock hits 52-week high at 5.47 USD - Investing.com
Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason - Insider Monkey
Precigen Gains FDA Orphan Drug Exclusivity for Gene Therapy Candidate PAPZIMEOSDebt Analysis Report - Město Břeclav
Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS - Insider Monkey
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):